We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
+13.99%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$7.33B
AUM Growth
+$796M
(+12%)
Cap. Flow
-$12M
Cap. Flow
% of AUM
-0.16%
Top 10 Holdings %
Top 10 Hldgs %
60.07%
Holding
377
New
123
Increased
61
Reduced
77
Closed
82
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$68.6M |
| 2 |
argenx
ARGX
|
+$55M |
| 3 |
Sanofi
SNY
|
+$50.7M |
| 4 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
+$50.5M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
+$42.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$48.6M |
| 2 |
Keurig Dr Pepper
KDP
|
+$45.5M |
| 3 |
Incyte
INCY
|
+$45.2M |
| 4 |
UnitedHealth
UNH
|
+$37.3M |
| 5 |
Campbell Soup
CPB
|
+$32M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.97% |
| 2 | Consumer Staples | 5.35% |
| 3 | Consumer Discretionary | 4.92% |
| 4 | Technology | 3.86% |
| 5 | Communication Services | 1.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Madrigal Pharmaceuticals
MDGL
$11.9B
| $11.6M | 0.16% |
50,000
-58,000
| -54% | -$10.1M |
|
77
Shake Shack
SHAK
$2.86B
| $11.2M | 0.15% |
+151,284
| New | +$9.28M |
|
78
Dyne Therapeutics
DYN
$4.82B
| $11M | 0.15% |
824,000
-376,000
| -31% | -$3.67M |
|
79
Intuitive Surgical
ISRG
$132B
| $10.8M | 0.15% |
32,000
-65,212
| -67% | -$19.4M |
|
80
Workday
WDAY
$41.6B
| $10.5M | 0.14% |
38,118
-33,835
| -47% | -$8.06M |
|
81
CRISPR Therapeutics
CRSP
$5.05B
| $10.5M | 0.14% |
168,000
-432,012
| -72% | -$23.9M |
|
82
Academy Sports + Outdoors
ASO
$2.97B
| $10.5M | 0.14% |
+158,668
| New | +$8.05M |
|
83
SentinelOne
S
$7.05B
| $10.2M | 0.14% |
372,000
-1,320,497
| -78% | -$25.6M |
|
84
Kenvue
KVUE
$36.7B
| $10.1M | 0.14% |
+470,000
| New | +$9.41M |
|
85
Prothena Corp
PRTA
$438M
| $10.1M | 0.14% |
+278,000
| New | +$10.7M |
|
86
Uber
UBER
$144B
| $10.1M | 0.14% |
164,000
-270,130
| -62% | -$14.1M |
|
|
MOR
87
CALL
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $9.9M | 0.14% |
+1,000,000
| New | +$7.35M |
|
88
NVIDIA
NVDA
$5.34T
| $9.89M | 0.14% |
199,770
+20,980
| +12% | +$972K |
|
|
FL
89
DELISTED
Foot Locker
FL
| $9.89M | 0.14% |
317,574
-347,083
| -52% | -$8.38M |
|
|
MURA
90
DELISTED
Mural Oncology
MURA
| $9.82M | 0.13% |
+1,658,000
| New | +$6.67M |
|
91
Wyndham Hotels & Resorts
WH
$5.63B
| $9.65M | 0.13% |
+120,000
| New | +$9.03M |
|
92
Wynn Resorts
WYNN
$10.6B
| $9.58M | 0.13% |
105,155
+49,155
| +88% | +$4.36M |
|
|
ESPR
93
DELISTED
Esperion Therapeutics
ESPR
| $9.57M | 0.13% |
+3,200,000
| New | +$4.15M |
|
94
BILL Holdings
BILL
$4.67B
| $9.31M | 0.13% |
+114,114
| New | +$9.37M |
|
|
HYPD
95
Hyperion DeFi Inc
HYPD
$40.3M
| $9.11M | 0.12% |
54,725
+16,137
| +42% | +$1.9M |
|
|
RVPH
96
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
| $9.08M | 0.12% |
88,200
+58,200
| +194% | +$5.22M |
|
|
KYNB
97
Kyntra Bio
KYNB
$28.3M
| $8.65M | 0.12% |
390,560
+74,880
| +24% | +$1.13M |
|
98
Adobe
ADBE
$102B
| $8.6M | 0.12% |
14,408
-3,396
| -19% | -$1.96M |
|
99
Zura Bio
ZURA
$542M
| $8.52M | 0.12% |
1,824,000
+244,000
| +15% | +$1.22M |
|
100
Charles River Laboratories
CRL
$12.5B
| $8.51M | 0.12% |
36,000
-120,000
| -77% | -$23.6M |
|
Similar funds
CRC
RMDI
F
EW
O
DSC
ACM
PI
Armistice Capital's Q4 2023 Portfolio in Review
As of Q4 2023, Armistice Capital held 377 positions worth $7.33B, up 12% from $6.53B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Armistice Capital's Q4 2023 filing shows 123 new, 61 increased, 77 reduced and 82 closed positions. Its largest new stake was Sanofi: 1,036,000 shares worth $51.5M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $48.6M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 34% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
- Armistice Capital's largest Q4 2023 buy was Sanofi: 1,036,000 shares worth $51.5M.
- Armistice Capital added most to GSK in Q4 2023, an estimated $68.6M increase.
- Armistice Capital's biggest Q4 2023 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $48.6M.
- Armistice Capital fully exited Keurig Dr Pepper in Q4 2023, selling an estimated $45.5M.
- Armistice Capital's ten largest holdings make up 60% of its $7.33B portfolio in Q4 2023.
- Armistice Capital opened 123 new positions and closed 82 in Q4 2023.
- Armistice Capital's portfolio value rose 12% quarter-over-quarter to $7.33B.
Based on Armistice Capital's 13F filing for Q4 2023, filed 13 Feb 2024.